Opinion|Videos|December 18, 2024
The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
Panelists discuss how health care centers provide comprehensive long-term monitoring and support services for both patients receiving CAR T and their caregivers in the posttreatment period, including regular medical assessments and ongoing educational resources.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What specific long-term monitoring protocols and support services does your center provide for patients undergoing CAR T and their caregivers in the months and years following treatment (eg, monitoring and care, support services, caregiver education, etc)?
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
3
Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option
4
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
5